Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

22P - Dynamics of indicators of the immune status in patients with metastatic solid tumours on the background of stereotactic ablative radiation therapy

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Anton Zozulya

Citation

Annals of Oncology (2020) 31 (suppl_7): S1417-S1424. 10.1016/annonc/annonc389

Authors

A. Zozulya1, I. Baldueva2, S. Novikov2, D. Girdyuk2, N. Emelyanova2

Author affiliations

  • 1 Oncoimmunology, N.N. Petrov National Medical Research Center of Oncology, 197758 - Saint-Petersburg/RU
  • 2 N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg/RU
More

Abstract 22P

Background

Stereotactic ablative radiation therapy (SABR) is actively used for treatment of patients with oligometastatic tumor process. It is assumed, that in addition to the direct effect on the tumor site, SABR can enhance the formation of an antitumor immune response. In this regard, the aim of our study is investigation of SABR’s influence on indicators of the immune status in patients with metastatic solid tumors.

Methods

We performed a preliminary analysis of the immunological parameters of blood before irradiation (point A), via 3-4 weeks (point B) and via 6-8 weeks (point C) after SBRT in 29 patients with malignant tumors with oligometastases in the liver and lungs. Radiotherapy was performed on the linear accelerator “Novalis Tx” EX = 6 MeV, all peripheral blood samples (87) were analyzed by flow cytometry on a FACS Canto ™ II cytometer. We used Friedman test for multiple comparison and Nemenyi test for between-group comparison. Data processing and statistical analysis was performed using Microsoft Excel 2010 and R (ver. 4.0.2).

Results

We observed statistically significant increase of T-lymphocytes (CD3+CD19-), χ2 = 13,8, p = 0,001, pairwise p(A, B) = 0,002; T-helpers (CD3+CD4+), χ2 = 8,2, p = 0,017, pairwise p(A, B) = 0,019; activated T-helpers (CD3+CD4+HLA-DR+), χ2 = 30,1; p < 0,001; pairwise p(A, B) < 0,001, p(A, C) < 0.001; activated cytotoxic T lymphocytes (CD3+СD8+HLA-DR+), χ2 = 13,3; p = 0,001; pairwise p(A, B) = 0,003, p(A, C) = 0.007; and decrease of B-lymphocytes (CD3-CD19+), χ2 = 31,5; p < 0,001, pairwise p(A, B) < 0,001, p(A, C) = 0.006. Interesting, that 6-8 weeks after SABR, in comparison with valued obtained 3-4 weeks after SABR, we detected statistically significant decrease of T-lymphocytes (pairwise p(B, C) = 0.01) and increase of B-lymphocytes (pairwise p(B, C) = 0.034).

Conclusions

Thus, revealed dynamics of immunological parameters indicates the induction of the T-cell link of antitumor immunity against decreasing of indicators of humoral immunity.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.